1. Division of Infectious Diseases Division of Infectious Diseases Department of Medicine  Gary Simon  David Parenti  Carmen Tuazon  Afsoon Roberts  Angelike Liappis  Fred Gordin  Virginia Kan  Cynthia Gibert  Debra Benator  Anne Labriola

2. Division of Infectious Diseases HIV/AIDS Clinical Services GWU Hospital 371 beds 15,000 admissions/yr VAMC Hospital 120 beds Medical Faculty Associates (MFA) –Ambulatory Care Building (ACC) 280 physicians 41 medical specialties 1,500 patients/day

3. Division of Infectious Diseases HIV/AIDS Clinical Services Infectious Diseases Clinic Outpatient management of antiretroviral therapy (ARVT) Treatment of naïve and ARVT experienced 800 HIV/AIDS patients at GWU »30% women »50% African American »15% Hepatitis C co-infection »12% Hepatitis B co-infection –800 HIV/AIDS patients at the VAMC Opportunistic infection therapy/prevention Infectious Diseases Clinic Outpatient management of antiretroviral therapy (ARVT) Treatment of naïve and ARVT experienced 800 HIV/AIDS patients at GWU »30% women »50% African American »15% Hepatitis C co-infection »12% Hepatitis B co-infection –800 HIV/AIDS patients at the VAMC Opportunistic infection therapy/prevention

4. Division of Infectious Diseases HIV/AIDS Clinical Services GWU/MFA Clinical Trials Unit (CTU) Three FT study coordinators –Suzanne Schuck, RN MPH –Nicole Bisby –Aimee Desrosiers, PAC MPH Phlebotomy lab, two – 80˚C freezers, adjacent to clinic Investigator-initiated projects and Phase I-IV clinical trials ID Research Laboratory Ross 705 Bona Yoon, research associate Translational projects VAMC Clinical Trials Unit (CPCRA) VA Research Laboratory Clinical applications and translational research projects –Flow cytometry/CD4 –HIV quantitation by bDNA assay –HIV genotypic resistance testing –HCV quantitation –HCV genotyping by real-time PCR

5. Division of Infectious Diseases HIV/AIDS Clinical Services Infectious Diseases Clinic Active HIV/AIDS research initiatives –Studies involving: new drugs/drug classes, vaccines, immunomodulating therapies –Pro-atherogenic potential of antiretroviral drugs (R01 HL65955) –Immune reconstitution mediated events, opportunistic infection Propose new bedside-to-bench initiatives: host and viral factors affecting viral load and the response to therapy New programs being developed –Application October, 2006 Ryan White funding –Expanding the treatment of infectious hepatitis Infectious Diseases Clinic Active HIV/AIDS research initiatives –Studies involving: new drugs/drug classes, vaccines, immunomodulating therapies –Pro-atherogenic potential of antiretroviral drugs (R01 HL65955) –Immune reconstitution mediated events, opportunistic infection Propose new bedside-to-bench initiatives: host and viral factors affecting viral load and the response to therapy New programs being developed –Application October, 2006 Ryan White funding –Expanding the treatment of infectious hepatitis

6. Division of Infectious Diseases HIV/AIDS Clinical Services ID Hospital consultation service ~ 100 consultations/month –~ 50% of consults for HIV/AIDS, all services –Majority are for the management of complications of untreated or undiagnosed HIV/AIDS New programs being developed –Determining barriers to healthcare access for hospitalized patients with end-stage HIV/AIDS –Predictors of non-compliance with clinical follow- up after hospitalization ID Hospital consultation service ~ 100 consultations/month –~ 50% of consults for HIV/AIDS, all services –Majority are for the management of complications of untreated or undiagnosed HIV/AIDS New programs being developed –Determining barriers to healthcare access for hospitalized patients with end-stage HIV/AIDS –Predictors of non-compliance with clinical follow- up after hospitalization